Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more
Ever Supreme Bio Technology Co. Ltd (6712) - Net Assets
Latest net assets as of June 2024: NT$1.54 Billion TWD
Based on the latest financial reports, Ever Supreme Bio Technology Co. Ltd (6712) has net assets worth NT$1.54 Billion TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.80 Billion) and total liabilities (NT$261.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.54 Billion |
| % of Total Assets | 85.5% |
| Annual Growth Rate | 33.17% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 68.17 |
Ever Supreme Bio Technology Co. Ltd - Net Assets Trend (2020–2023)
This chart illustrates how Ever Supreme Bio Technology Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ever Supreme Bio Technology Co. Ltd (2020–2023)
The table below shows the annual net assets of Ever Supreme Bio Technology Co. Ltd from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.84 Billion | +2.83% |
| 2022-12-31 | NT$1.79 Billion | -5.57% |
| 2021-12-31 | NT$1.90 Billion | +143.07% |
| 2020-12-31 | NT$780.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ever Supreme Bio Technology Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 62452800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$323.67 Million | 17.56% |
| Common Stock | NT$733.39 Million | 39.79% |
| Other Components | NT$785.91 Million | 42.64% |
| Total Equity | NT$1.84 Billion | 100.00% |
Ever Supreme Bio Technology Co. Ltd Competitors by Market Cap
The table below lists competitors of Ever Supreme Bio Technology Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Jianan Electronics Co Ltd
SHE:300880
|
$268.70 Million |
|
ZINZINO AB B
F:9EE
|
$268.71 Million |
|
Multiconsult ASA
LSE:0R8N
|
$268.78 Million |
|
Jiangsu Beiren Robot System Co Ltd
SHG:688218
|
$268.88 Million |
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
$268.59 Million |
|
Shihlin Paper Corp
TW:1903
|
$268.57 Million |
|
Shenzhen Zhongheng Huafa Co Ltd Class A
SHE:000020
|
$268.56 Million |
|
Besalco Sa
SN:BESALCO
|
$268.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ever Supreme Bio Technology Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,792,170,000 to 1,842,961,000, a change of 50,791,000 (2.8%).
- Net income of 539,397,000 contributed positively to equity growth.
- Dividend payments of 136,289,000 reduced retained earnings.
- Share repurchases of 356,354,000 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$539.40 Million | +29.27% |
| Dividends Paid | NT$136.29 Million | -7.4% |
| Share Repurchases | NT$356.35 Million | -19.34% |
| Other Changes | NT$4.04 Million | +0.22% |
| Total Change | NT$- | 2.83% |
Book Value vs Market Value Analysis
This analysis compares Ever Supreme Bio Technology Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.20x to 5.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$11.52 | NT$140.50 | x |
| 2021-12-31 | NT$25.21 | NT$140.50 | x |
| 2022-12-31 | NT$23.78 | NT$140.50 | x |
| 2023-12-31 | NT$24.66 | NT$140.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ever Supreme Bio Technology Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 29.27%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 71.12%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.13x
- Recent ROE (29.27%) is above the historical average (11.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -13.68% | -151.32% | 0.08x | 1.10x | NT$-184.91 Million |
| 2021 | 19.48% | 84.22% | 0.22x | 1.07x | NT$179.82 Million |
| 2022 | 11.20% | 31.99% | 0.32x | 1.10x | NT$21.50 Million |
| 2023 | 29.27% | 71.12% | 0.37x | 1.13x | NT$355.10 Million |
Industry Comparison
This section compares Ever Supreme Bio Technology Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ever Supreme Bio Technology Co. Ltd (6712) | NT$1.54 Billion | -13.68% | 0.17x | $268.60 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |